Published as a 2023 in Nature Biopharma Dealmakers, this article presents Quibim’s approach to transforming medical imaging data into actionable predictions for precision medicine and drug development.

At the core of this strategy is an AI-powered ecosystem that connects imaging with clinical and multi-omics data, while addressing one of the major challenges in medical imaging AI: variability across scanners, vendors and institutions. Image harmonization, automated organ and lesion segmentation, radiomics feature extraction and predictive modeling form an integrated pipeline designed to generate robust imaging biomarkers.

The article highlights how this approach can support biopharma beyond conventional image analysis. By linking imaging phenotypes with clinical outcomes, Quibim aims to develop predictive biomarker panels, including models for treatment-response prediction and patient stratification.

A key differentiator is the combination of large-scale imaging data, AI technology and strategic partnerships, with external validation across independent healthcare sites emphasized as essential for model generalizability.

The feature illustrates a broader vision for medical imaging: moving from images used primarily for diagnosis toward quantitative, predictive data capable of supporting clinical trials, companion diagnostics and personalized patient care.